Program
Anti-PD-L1/Anti-Vd1 T-cell Engager TAK-505
Its studies are led by Takeda.
Furthest: phase 2, since Feb 5, 20261 company-led study, 1 open or runningNext primary completion: Aug 18, 2030 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 11 open or running | phase 2since Feb 5, 2026 | Feb 5, 2026 | Aug 18, 2030phase 2 · NCT07436728 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 5, 2026First study: phase 2 study in Malignant Solid TumorsFirst studyNCT07436728 · 151 planned · United States
Ahead
- Aug 18, 2030Primary completion: phase 2 study in Malignant Solid TumorsNCT07436728
TargetBeta
“A bispecific antibody and T-cell engager (TCE) targeting the immune checkpoint protein human programmed death-ligand 1 (PD-L1; cluster of differentiation 274; CD274) and the variable delta 1 (Vd1; Vdelta1; TRDV1) segment of the gamma-delta (gd) T-cell receptor (TCR) on gdT-lymphocytes, ”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07436728Malignant Solid Tumors · United States | 2 | Recruiting | Aug 18, 2030 | 151 |
How it is read
Names in the registry
- “TAK-505”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.